Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Value of Pre-symptomatic Genetic Risk Assessment for Age-Related Macular Degeneration

NCT05265624 is registered in ClinicalTrials.gov with Paul S. Bernstein as lead sponsor.

NCT NCT05265624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05265624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Value of Pre-symptomatic Genetic Risk Assessment for Age-Related Macular Degeneration
Lead sponsor
Paul S. Bernstein
Phase
Phase 2
Overall status
Completed
Start date
August 3, 2022
Completion date
July 12, 2024
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, genetic testing, nutritional biomarkers